Streetbeat News

Stock Prices

ACET

ANIP

NVS

SUPN

Several top Wall Street analysts have downgraded their ratings for notable companies, including Adicet Bio, Novartis, Supernus Pharmaceuticals, and ANI Pharmaceuticals. These downgrades have led to declines in the respective stock prices.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 4:13 pm

BCTX

PCT

RTO

TBIO

U.S. stocks mostly fell with the S&P 500 down 0.5%. Notable stock movements include PureCycle Technologies up 32% after a financing update, BriaCell Therapeutics up 109% on positive clinical data, and Telesis Bio down 58% after announcing a delisting. Rentokil Initial shares fell 21% after revising guidance.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 4:13 pm

BNTX

GSK

MRNA

GSK has halted its herpes simplex virus vaccine development, clearing the way for competitors like Moderna and BioNTech. GSK's vaccine did not meet efficacy goals, but no safety issues were found. Moderna and BioNTech continue their HSV vaccine trials.

Portfolio Pulse from Vandana Singh

September 11, 2024 | 4:13 pm

GME

GameStop shares fell after the company reported lower-than-expected revenue for Q2 2024, despite beating EPS estimates. Revenue was $798 million, missing the $895.67 million estimate. Wedbush analyst lowered the price target from $11 to $10.

Portfolio Pulse from Dylan Berman

September 11, 2024 | 4:12 pm

HPP

Hudson Pacific Properties (NYSE:HPP) has received mixed analyst ratings over the past three months, with a majority being indifferent. Analysts have lowered their price targets, reflecting concerns over the company's financial performance, including declining revenues and profitability challenges. The average price target has decreased from $6.38 to $5.31.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 4:00 pm

PANW

Deep-pocketed investors are showing a bearish sentiment towards Palo Alto Networks (PANW), with significant options activity indicating potential market movements. The stock is currently trading at $336.89, down 3.08%, with analysts providing mixed ratings and price targets ranging from $345 to $416.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 4:00 pm

PGR

Progressive (NYSE:PGR) has significantly outperformed the market over the past decade, with an annualized return of 25.59%. A $1000 investment in PGR 10 years ago would now be worth $9,779.50. This highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 4:00 pm

ZION

Analysts have mixed views on Zions Bancorp (NASDAQ:ZION), with most ratings being indifferent. Recent price target adjustments show an upward trend, with an average target of $51.14, a 10.84% increase from the previous target. Zions Bancorp faces challenges in revenue growth and net margin but shows strong ROE and a sound debt structure.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 4:00 pm

WFC

Recent options trading trends for Wells Fargo (NYSE:WFC) show a bearish sentiment among large investors, with 52% of trades being bearish. The stock is currently trading at $52.7, down 2.33%. Analysts have set a price target of $65, with Deutsche Bank upgrading its rating to Buy.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 4:00 pm

AMT

American Tower (NYSE:AMT) has delivered an average annual return of 13.28% over the past 15 years, outperforming the market by 1.83% annually. A $1000 investment in AMT 15 years ago would now be worth $6,654.56. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 4:00 pm